**What's Known**

HUCB contains various stem progenitor cells with the ability to differentiate into both hematopoietic and non-hematopoietic cells.Transplantation of cord blood cells may offer an attractive route for cell therapy.miRNAs play a key role in hematopoiesis and new evidence on specific miRNA expression in this process is available.

**What's New**

The precise function of miRNAs in hematopoiesis is relatively unknown and many of the individual targets of miRNA within the mentioned mechanism have not yet been identified.Despite evidence implicating miRNAs in miscellaneous physiological mechanisms, alterations of expression profiles *in vitro* have not been well characterized.Assessment of miRNA profiles is helpful for the recognition of changes that may cause unfavorable functions.

Introduction {#sec1-1}
============

Molecular and genetic studies carried out in the past 2 decades have shown different regulatory processes of hematopoiesis.^[@ref1]-[@ref3]^ MicroRNAs (miRNAs) are small endogenous noncoding RNAs containing 20--23 nucleotides that operate post-transcriptionally and have emerged as a new mode of gene regulation. They are encoded at different genomic regions and bind to the 3′untranslated part of their target genes via base pairing for tuning numerous pathways that relate to the development of diseases or function as master switches that turn genes on and off.^[@ref4]^ It is predicted by bioinformatic analysis that about 5% of transcriptome is for miRNAs and that the translation of more than one-third of human messenger RNAs (mRNAs) is regulated by thesemiRNAs.^[@ref5],[@ref6]^ The epigenetic effects of miRNAs during multiple biological functions such as differentiation and development have long been studied.^[@ref7]-[@ref9]^ miRNAs are usually expressed in a tissue-specific manner and sometimes during certain developmental stages.^[@ref10]^ Generally, one miRNA can target several mRNAs, often in combination with other miRNAs. This indicates that miRNAs function in highly complex regulatory networks. Although the functions and target genes of most miRNAs are still unknown, they have been implicated in many diverse processes, including differentiation and organogenesis, developmental timing, growth control, apoptosis, patterning and embryogenesis, viral infections, and cancer.^[@ref7],[@ref11]^ For example, mir-140 has been expressed more in the development of mouse cartilage,^[@ref12]^ miR-145 has been reported to regulate adipocyte differentiation,^[@ref13]^ miR-133 regulates skeletal differentiation,^[@ref14]^ miR-206 regulates muscle differentiation,^[@ref15]^ miR-1 regulates cardiac morphogenesis and the cardiac cell cycle,^[@ref16]^ and miR-155 is associated with immune system development,^[@ref17]^ while mir-221 has been identified as a regulator in osteogenic differentiation.^[@ref9]^ Despite evidence implicating miRNAs in miscellaneous physiological mechanisms, the alterations of expression profiles *in vitro* have not been well characterized and are poorly understood. An assessment of miRNA profiles is helpful for the recognition of changes that may cause unfavorable functions. Human umbilical cord blood (HUCB), a byproduct of childbirth, is an acceptable and readily accessible source of stem cells.^[@ref18]^ Human leukocyte antigen (HLA) typing of cord blood for storage has raised hope for patients to access an HLA-matching cell source. Recently, it has been observed that HUCB contains various stem progenitor cells with the ability to differentiate into both hematopoietic and non-hematopoietic cells.^[@ref19]-[@ref23]^ Thus, the transplantation of cord blood cells may offer an attractive route for cell therapy. However, the current dearth of knowledge regarding the probable alterations during laboratory processes has limited their use in practical applications (i.e., hematological diseases). We sought to study the possible changes in miRNA expression profiles of CD133+ hematopoietic cells *in vitro*. An assessment of miRNA profiles is helpful for the recognition of changes that may cause unfavorable functions.

Materials and Methods {#sec1-2}
=====================

*Sample Preparation* {#sec2-1}
--------------------

With informed consent of the mother, an umbilical cord blood sample of a normal full-term delivery was collected in blood bags containing sodium citrate and then diluted with hydroxyethyl starch in a ratio of 1:4 in order to deplete red blood cells. Mononuclear cells (MNCs) were separated from the diluted sample using Ficoll-Paque (Inno-Train) density gradient centrifugation for 30 minutes at 400×gat 20°C. The MNC interface layer was collected and washed twice with PBS/EDTA.

*Isolation and Expansion of CD133^+^ Cells* {#sec2-2}
-------------------------------------------

The MNCs were incubated with magnetic CD133 antibody-conjugated microbeads (Miltenyi Biotec) according to the manufacturer's instructions. The adherent CD133^+^ cells were diluted in 1 mL of Hank's Buffered Salt Solution (HBSS); the cells were counted and their purity was assessed using flowcytometry (Sample 1). Then, the cells were cultured in 24-well plates with a Stem-Span culture medium(Stem Cell Technologies, Vancouver, BC, Canada)supplemented with Flt3, TPO, and SCF for 12 days. On day 12, the expanded population was evaluated by flowcytometry again (Sample3). Subsequently, for the second time, the CD133^+^ cells were isolated from the expanded cells by magnetic microbeads and the purity of the isolated population was determined by flowcytometry (Sample 2).

*Flowcytometry Analysis* {#sec2-3}
------------------------

A total of 2×10^5^ cells were divided into aliquots in amber-tinted 5-mL centrifuge tubes, and 3% human serum was added. The cells were incubated for 30 minutes, resuspended in 5mLof PBS, and pelleted by centrifugation for 10 minutes at 300×g. Thereafter, the cells were resuspended in 100 µL of PBS and stained with PE-conjugated anti-human CD133 (Miltenyi Biotec) at 4°C for 30 minutes. Some cells were stained with MultiMix mouse IgG1 RPE (Dako) and were used as negative controls. The cells were then pelleted, washed twice with PBS, and fixed with 1% paraformaldehyde in PBS. After fixation, flowcytometry analysis was performed on a FACSCalibur cytometer (Becton Dickinson) using CellQuest software. Win MDI 2.8 software was used to create histograms.

*RNA Isolation* {#sec2-4}
---------------

RNA was isolated using TRIzol (Invitrogen, USA) according to the manufacturer's protocol. The synthesis of cDNA was carried out with an miRNA cDNA synthesis kit G269 (Applied Biological Materials, Richmond, BC, Canada).

*Quantitative Evaluations of MicroRNA Expressions* {#sec2-5}
--------------------------------------------------

Real-time PCR for miRNA assay was carried out using an Applied Biological Materials miRNA profiling kit (MA003, Richmond, BC, Canada) and the StepOnePlus Real-Time RT-PCR system (Applied Biosystems, USA). All the reactions were run in triplicate, and the threshold cycle average was used for data analysis. The relative expressions of the miRNAs were normalized using the 4endogenous miRNA controls on each plate for each sample.

*qPCR Data Analysis* {#sec2-6}
--------------------

The resulting threshold cycle values for all the wells were exported to an Excel Spreadsheet. The miRNA qPCR data were analyzed with the 2^--∆∆CT^ method using the miRNA qPCR Array Data Analysis Excel, provided by the Applied Biological Materials website (<http://www.abmgood.com/>).

*miRNA Target Prediction* {#sec2-7}
-------------------------

Putative targets of the candidate miRNAs that showed highly modulated expression after 12 days' culture of the CD133^+^ cells compared to the fresh isolated cells were found using TargetScan (<http://genes.mit.edu/targetscan>) and miRBase (<http://www.mirbase.org>) online software.

*Pathway Analysis* {#sec2-8}
------------------

In order to indicate the cellular pathways related to the putative targets of the most modulated miRNAs (mir-106a, mir-16, mir-146a, mir-222, mir-223, and mir-125a), we used the online *in-silico* software of DIANA-miRPath (<http://diana.cslab.ece.ntua.gr/pathways/>).

*Statistical Analysis* {#sec2-9}
----------------------

The data are shown as mean±SD for the independent measurements. The statistical analyses were performed using the Student *t*-test by SPSS, version 13.0. A P value \<0.05 was considered significant.

Results {#sec1-3}
=======

*Isolation and Evaluation of Isolated CD133^+^ Cells* {#sec2-10}
-----------------------------------------------------

The ratio of cell isolation was 1 million CD133^+^ cells per 85 million total nucleotide HUCB cells. The first isolation of the CD133^+^ cells by microbeads resulted in spherical cells on day one. Flowcytometry analysis of this population (Sample 1) showed 98% purity ([figure 1](#F1){ref-type="fig"}). After 12 days' culture, flowcytometry analysis indicated that 36% of the expanded cells wereCD133^+^ (Sample 3). These cells were passed through a microbead column in order to isolate the CD133^+^ cells for the second time (Sample 2): the purity of the isolated cells was 97% ([figure 2](#F2){ref-type="fig"}).

![Phase contrast microscopy of the isolated CD133^+^ cells (A) and the flow cytometry analysis of the microbead isolated CD133^+^ cells (Sample 1) compared to the whole population (B) are illustrated. The first isolation of the CD133^+^cells by microbeads resulted in spherical cells on day one. Flowcytometry analysis of this population showed 98% purity. Colored areas: isotype; white areas: CD133^+^ cells.](IJMS-42-40-g001){#F1}

![Flowcytometry analysis of the 12-day in vitro culture of the sample (Sample 3) and the second microbead isolated CD133^+^ cells (Sample 2) shows 36% and 97% purity, respectively. Colored areas: isotype; white areas: CD133^+^ cells.](IJMS-42-40-g002){#F2}

*Evaluation of miRNA Expression Profiling* {#sec2-11}
------------------------------------------

The microRNA expression profiling of the CD133^+^ cells on day1 and day 12 (Sample 1 and Sample 2, respectively) showed modulation of a broad cohort of miRNAs, which predicted hematopoietic targets. Among 1,151 screened miRNAs in Sample1 versus Sample 3, 349 miRNAs were upregulated, while the expression of 293 miRNAs was downregulated; the expression of 509 miRNAs was not significantly changed. Some miRNAs were chosen because of their reported roles in hematopoiesis mechanisms ([table 1](#T1){ref-type="table"}). Their expression levels and also their expression trends after *in vitro* culture are illustrated in [table 2](#T2){ref-type="table"}. In addition, their chromosomal locations and overlapping transcripts are shown in [table 3](#T3){ref-type="table"}.

###### 

Selected hematopoietic miRNAs and their related putative targets

  microRNA (hsa)     Putative targets[\*](#t1f1){ref-type="table-fn"}   Functions
  ------------------ -------------------------------------------------- ------------------------------------------------------------------------------------------------
  mir-10a            HOXA1                                              Megakaryocytic differentiation
  mir-34a            CDK4, CDK6, MYB                                    Megakaryocytic differentiation
  mir-223            LMO2, NFI-A                                        Regulation of erythroid and megakaryocytic differentiation
  mir-24             activin type I receptor ALK4                       Inhibition of erythropoiesis
  mir-221, mir-222   KIT                                                Inhibition of erythropoiesis
  mir-155            ETS-1, MEIS1                                       Inhibition of myelopoiesis and erythropoiesis
  mir-16             MYB                                                Contribution in erythropoiesis
  mir-451            GATA1                                              Contribution in erythropoiesis
  mir-125b           BMF, KLF13, Lin28A                                 Regulation of hematopoiesis
  mir-17-5p          BCL2                                               Promotion of hematopoietic cell expansion
  mir-106a           BCL2                                               Promotion of hematopoietic cell expansion
  mir-144            GATA1                                              Function in erythroid phenotype
  mir-424            NFI-A                                              Regulation of monocyte/macrophage differentiation
  mir-181            HOXA5                                              Inhibitory effect on hematopoietic differentiation
  mir-29a            HBP1, FZD5, TPM1                                   Acquisition of self-renewal capacity by myeloid progenitors
  mir-146            PROM1                                              Proliferation of CD133^+^
  mir-196a           HOXA9                                              Related to pediatric acute lymphoblastic leukemia and participation in myeloid differentiation
  mir-15             BCL2                                               Related to chronic lymphocytic leukemia
  mir-150            MYB                                                Inhibition of leukemogenesis

Selected putative targets are predicted using Target scan and mirBase online websites

###### 

Expression levels of the selected miRNAs before and after *in vitro* culture

  MicroRNA    Expression level in Sample 1   Expression level in Sample 2   Ratio of expressions in Sample 2 to Sample 1
  ----------- ------------------------------ ------------------------------ ----------------------------------------------
  mir-125a    2.67                           0.23                           0.1
  mir-125b    0.05                           0.01                           0.2
  mir-196b    0.1                            0.12                           1.2
  mir-29a     0.01                           0                              0
  mir-223     0.57                           1.81                           3.2
  mir-221     0.09                           0.07                           0.8
  mir-15      0.25                           0.14                           0.6
  mir-155     0.03                           0.05                           1.7
  mir-181     0.34                           0.1                            0.3
  mir-146     0.46                           1.81                           3.9
  mir-150     0.09                           0.03                           0.3
  mir-34      0.03                           0.02                           0.7
  mir-10a     0.01                           0.012                          1.2
  mir-24      0.26                           0.3                            1.1
  mir-222     4.4                            0.58                           0.1
  mir-144     0.02                           0.04                           2
  mir-16      0.03                           0.12                           4
  mir-451     0.13                           0.04                           0.3
  mir-424     0.2                            0.25                           1.2
  mir-17-5p   2.04                           2.05                           1
  mir-20a     0.99                           2.59                           2.6
  mir-106a    0.05                           0.57                           11.4

###### 

Accession numbers, chromosomal locations, and overlapping transcripts of the selected miRNAs

  MicroRNA (has)   Accession number   Chromosome/Overlapping transcripts
  ---------------- ------------------ ------------------------------------------------------------------------
  mir-125a         MI0000469          Chr19/antisense AC018755.2-201; exon 1
  mir-125b         MI0000446          Chr11/sense RP11-166D19.1-016; intron 1
  mir-196b         MI0001150          Chr7/sense RP1-170O19.21-004; intron 1
                                      Antisense HOXA-AS4-002; intron 1
  mir-520h         MI0003175          Chr19/intergenic
  mir-29a          MI0000087          Chr7/sense MIR29A-201; exon 1antisense AC016831.7-001; intron 2
  mir-223          MI0000300          chrX/sense AL034397.1-201; exon 2
  mir-221          MI0000298          chrX/intergenic
  mir-15           MI0000069          Chr13/sense DLEU2-001; intron 3
  mir-155          MI0000681          Chr21/sense MIR155HG-001; exon 4
  mir-181a         MI0000269          Chr9/sense MIR181A2HG-001; intron 1antisense NR6A1-001; intron 2
  mir-146          MI0000477          Chr5/sense CTC-231O11.1-001; exon 2
  mir-150          MI0000479          Chr19/intergenic
  mir-34           MI0000268          Chr1/intergenic
  mir-10a          MI0000266          Chr17/sense HOXB3-003; intron 1antisense RP11-357H14.7-012; intron 1
  mir-24           MI0000080          Chr9/sense C9orf3-007; intron 4antisense MIR24-1-201; exon 1
  mir-222          MI0000299          chrX/intergenic
  mir-144          MI0000460          Chr17/sense RP11-20B24.2-001; exon 1MIR451B-001; exon 1
  mir-16           MI0000070          Chr13/sense DLEU2-001; intron 3
  mir-451          MI0001729          Chr17/sense RP11-20B24.2-001; exon 1antisense RP11-20B24.9-001; exon 1
  mir-424          MI0001446          chrX/sense AC004383.4-001; exon 1
  mir-17-5p        MIMAT0000070       Chr13/sense MIR17HG-002; exon 2
  mir-20a          MI0000076          Chr13/sense MIR17HG-002; exon 2
  mir-106a         MI0000113          chrX/intergenic

Data from miRBase database (<http://www.mirbase.org>)

*Pathway Analysis* {#sec2-12}
------------------

Our investigation of the most modulated miRNAs using available online software indicated that the majority of the putative targets of the mentioned miRNAs were involved in the chronic myeloid leukemia (CML) pathway.

Discussion {#sec1-4}
==========

miRNAs are small 19--22 nucleotide non-coding, post-transcriptional regulatory RNA molecules which regulate gene expression and different biological processes, including development, proliferation, differentiation, and apoptosis, in various cells.^[@ref24]^ A better understanding of miRNA regulatory mechanisms in the pattern of gene expression during hematopoiesis will not only increase our knowledge regarding this phenomenon but also provide relevant information for therapeutic intervention.^[@ref25]^ MiRNAs play a key role in hematopoiesis; however, the precise function of miRNAs in hematopoiesis is relatively unknown, and many of the individual targets of miRNAs within the mentioned mechanism have not been identified yet.

Changes in expression patterns such as gene expression alterations after *in vitro* cell culture have been reported in several studies. These changes include cell growth arrest due to an increased expression of transforming growth factor beta (TGFβ1 and TGFβ2) followed by the inactivation of c-Myc through SMAD3 in human mesenchymal stem cells,^[@ref26]^ downregulation of cell-cycle quiescence and stemness-related genes and upregulation of signal transduction, cell adhesion, and cytoskeletal-related genes in human stromal stem cells.^[@ref27]^

There is also a significant alteration in gene expression profiles and a reduction in differences between myometrial and fibroid smooth muscle cells after *in vitro* cell culture. Downregulated genes include interleukin receptors IL10RB, IL11RA, and IL17R;TGFβR; platelet-activating factor receptor; tumor necrosis factor receptor superfamily 25; retinoic acid receptor-β; MYST3 and 4;Homeobox A10(HOXA10 and D4); SOX13; and TGFβ1/4. Upregulated genes include cell adhesion-related genes (ADM9/10 and THBS1/2) and cellular metabolism-related genes (fatty acid and lipid, carbohydrate, protein, and amino acid metabolism).^[@ref28]^

Despite these studies, there are no published studies on miRNA expression profiles after *in vitro* cell culture. Our study is the first study on miRNA expression profiles in HUCB cells after *in vitro* culture compared with that in fresh isolated CD133^+^ hematopoietic cells.

In the present study, the possible alterations in the miRNA profile of CD133^+^ hematopoietic cells were investigated via *in vitro* culture and expansion. To address this issue and uncover the related targets and pathways, we compared the miRNA expression patterns of CD133^+^ hematopoietic cells after isolation and after 12 days' *in vitro* culture. The microbead isolated CD133^+^ hematopoietic cells from HUCB (Sample 1) were spherical, and their purity analyzed by flow cytometry was 98% ([figure 1](#F1){ref-type="fig"}). The investigation of the 12 days' cultured cells by flow cytometry indicated that 36% of the population consisted of CD133+ cells (Sample 3, [figure 2](#F2){ref-type="fig"}). This decrease in the CD133^+^ population percentage may be explained by the more rapid proliferation of the other populations. Following a second isolation by beads, the purity of the CD133^+^ cells increased to 97% (Sample 2).

Based on our miRNA profiling data in general, the expression of about half of the analyzed miRNAs was significantly modulated in Sample 2 as compared to Sample 1.

We selected more than 20 miRNAs with the most expression alterations in Sample 2 and compared them to Sample 1 ([table 2](#T2){ref-type="table"}). The role of selected miRNAs in hematopoiesis has been reported in previous studies and is summarized in [table 1](#T1){ref-type="table"} according to TargetScan and miRBase online websites.

Mature miRNAs are associated with the RNA-induced silencing complex for loading onto 3´UTR of targeted mRNAs. Because of imperfect complementarity with their target mRNA, the prediction of miRNA targets is difficult.^[@ref29],[@ref30]^ Fortunately, significant progress in data mining has provided a wide range of bioinformatic analysis options to aid researchers in the interpretation of their data.^[@ref31]^ *In-silico* identification of genes targeted by miRNAs is widely believed to be an important step toward understanding the role of miRNAs in gene regulatory networks. Using online software, we predicted some hematopoietic-related targets of selected miRNAs and summarized them in [table 1](#T1){ref-type="table"}.

The initiation and activation of multiple intracellular pathways is necessary for the alteration in cell fate.^[@ref32]^ In addition to post-translational/translational regulations, miRNAs are another set of molecules for regulating the signaling pathways and play a role in physiological/pathological processes.^[@ref33]^ In this regard, we chose the 6most modulated miRNAs to find the related pathways using the DIANA-miRPath. According to the classification of the Kyoto Encyclopedia of Genes and Genomes (KEGG) Orthology in the KEGG databases (<http://www.genome.jp/kegg/>), the majority of the putative targets of these miRNAs were involved in the CML pathway.

Most human miRNAs lie between protein-coding genes (intergenic region), whereas about one-third lie within the introns of annotated mRNAs.^[@ref34]^ Strongly-correlated expression patterns have been observed between miRNAs and their host genes, and miRNAs are processed from the same primary transcripts as their host genes.^[@ref35]^ An investigation of the location of these top modulated miRNAs showed that the majority were located within their host genes, while only 6 miRNAs were intergenic ([table 3](#T3){ref-type="table"}).

Given that miRNAs participate in the molecular regulation of cell differentiation, proliferation, and death, it could be concluded that some important changes occurred in the CD133^+^ cells during *in vitro* culture. Because of the therapeutic applications of these cells, even minor modifications or alterations during laboratory adaptation (or processing) are essential and require illustration. Considering the important role of cellular environment for cell culture, providing and altering cellular conditions similar to the *in vivo* environment, for example by culturing and expanding cells in 3-dimensional collagen matrix, may decrease differences between *in vitro* and *in vivo* gene expression profiles such as miRNA expression. These cell culture conditions may provide a sufficient and appropriate environment for CD133^+^ hematopoietic stem cells with their clonogenicity and pluripotency potential for differentiating to different lineages. Soufizomorrod et al.^[@ref36]^ cultured CD133^+^umbilical cord blood cells in collagen-coated 3-dimensional scaffold and demonstrated the high expansion of these cells compared to routine cell culture (2-dimensional microenvironment).

Conclusion {#sec1-5}
==========

The present study is the first of its kind on miRNA profile modulations and their related pathway in *in vitro* cultured CD133+ cells. However, further screening is needed to provide precise details regarding the relation between post-transplantation disorders and miRNA profile modulations. Taking the results into account, this study could provide a basis for further research on the effects of 2-dimensional culture on hematopoietic cells before transplantation and the subsequent side effects or disorders that may be identified and prevented.
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